Subscribe

Subscribe to our Newsletter and get informed about new publication regulary and special discounts for subscribers!

ILCPA > Volume 68 > Synthesis, Characterization and Antimicrobial...
< Back to Volume

Synthesis, Characterization and Antimicrobial Activities of some Novel 3-(4-Bromobenzyl)-5-(Thiophen-2-yl)-4H-1,2,4-Triazol Derivatives

Full Text PDF

Abstract:

A convenient and promising synthesis of 4-(alkyl/aryl)- 3-(4-bromobenzyl)-5-(thiophen-2-yl)-4H-1,2,4-triazol was carried out by the reaction of 2-(4-bromobenzyl)-5-(thiophen-2-yl)-1,3,4-oxadiazole with different aliphatic/aromatic primary amine without any solvent. The newly synthesized compound were characterized by 1H NMR, IR and Mass spectroscopy and also screened for their antimicrobial activity against various strains of bacteria and fungi.

Info:

Periodical:
International Letters of Chemistry, Physics and Astronomy (Volume 68)
Pages:
10-17
Citation:
A. A. Kaneria et al., "Synthesis, Characterization and Antimicrobial Activities of some Novel 3-(4-Bromobenzyl)-5-(Thiophen-2-yl)-4H-1,2,4-Triazol Derivatives", International Letters of Chemistry, Physics and Astronomy, Vol. 68, pp. 10-17, 2016
Online since:
July 2016
Export:
Distribution:
References:

[1] A. K. Wahi and A. Singh, Triazole: Recent development and biological activities, Asian J. Biochem. Pharm. Res., vol. 1, no. 2, p.193–205, (2011).

[2] S. Maddila, R. Pagadala, and S. B. Jonnalagadda, 1 , 2 , 4-Triazoles : A review of synthetic approaches and the biological activity, Lett. Org. Chem., vol. 10, p.693–714, (2013).

[3] J. A. Bladin, Ueber verbindungen, welche sich vom dicyanphenylhydraein ableiten. III, Berichte, vol. 19, p.2598–2604, 1886.

[4] J. A. Bladin, Ueber von dicyanphenylhydmsin abgeleitete verbindungen., Berichte, vol. 18, p.1544–1551, 1885.

[5] I. L. Finar, Organic Chemistry, Volume 2: Stereochemistry and The Chemistry of Natural Products, Fifth addi. Pearson Education India, (1956).

[6] M. Asif, Recent advancement of potentially significant triazole derivatives, Discov. Chem., vol. 1, no. 1, p.18–32, (2015).

[7] A. R. Katritzky and C. W. Rees, Comprehensive Heterocyclic Chemistry, Forth addi. Elsevier Science Ltd., (1997).

[8] P. J. Goadsby, R. B. Lipton, and M. D. Ferrari, Migraine current understanding and treatment, N. Engl. J. Med., vol. 346, no. 4, p.257–270, (2002).

[9] D. K. J. Gorecki and R. K. Verbeeck, Trazodone hydrochloride, Anal. Profiles Drug Subst., vol. 16, p.693–730, (1987).

[10] R. N. Brogden, R. C. Heel, T. M. Speight, and G. S. Avery, Trazodone : A review of its pharmacological properties and therapeutic use in depression and anxiety, Drugs, vol. 21, no. 6, p.401–429, (1981).

[11] O. Geyer, A. Loewenstein, B. Shalmon, M. Neudorfer, and M. Lazar, The additive miotic effects of dapiprazole and pilocarpine, " Graefe, s Arch. Clin. Exp. Ophthalmol., vol. 233, p.448–451, (1995).

[12] J. T. Witkowski, R. K. Robins, R. W. Sidwell, and L. N. Simon, Design, synthesis, and broad spectrum antiviral activity of 1 -P-β-D-Ribofuranosyl- 1, 2, 4-triazole-3-carboxamide and Related Nucleosides, J. Med. Chem., vol. 15, no. 11, p.1150–1154, (1972).

[13] M. Terasawa, H. Aratani, M. Setoguchi, and T. Tahara, Pharmacological actions of Y-24180: I. A potent and specific antagonist of platelet-activating factor, Prostaglandins, vol. 40, no. 6, p.553–569, (1990).

[14] R. Das and D. Mehta, New insights into anti-tubercular potential of triazole scaffold, World J. Pharm. Res., vol. 4, no. 1, p.1536–1570, (2015).

[15] K. Hirai, H. Sugimoto, T. Ishiba, T. Fujishita, Y. Tsukinoki, and K. Hirose, Synthesis and biological activity of (3, 5-Disubstituted-1h-1, 2, 4-Triazole-1-yl)benzophenone derivatives, J. Heterocycl. Chem., vol. 19, p.1363–1369, (1982).

[16] J. M. Nabholtz, A. Buzdar, M. Pollak, W. Harwin, G. Burton, A. Mangalik, M. Steinberg, A. Webster, and M. von Euler, Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women : Results of a north american multicenter, J. Clin. Oncol., vol. 18, no. 22, p.3758–3767, (2000).

[17] P. E. Goss, Pre-clinical and clinical review of vorozole, a new third generation aromatase inhibitor, Breast Cancer Res. Treat., vol. 49, pp. S59–S65, (1998).

[18] A. S. Bhatnagar, A. Hausler, K. Schieweck, M. Lang, and R. Bowman, Highly selective inhibition of estrogen biosynthesis by CGS 20267, a new non-steroidal aromatase inhibitor, J. Steroid Biochem. Mol. Biol., vol. 37, no. 6, p.1021–1027, (1990).

[19] P. E. Goss, J. N. Ingle, S. Martino, N. J. Robert, H. B. Muss, M. J. Piccart, M. Castiglione, D. Tu, lois E. Shepherd, K. I. Pritchard, robert B. Livingston, N. E. Davidson, L. Norton, E. A. Perez, J. S. Abrams, P. Therasse, M. J. Palmer, and J. L. Pater, A randomized trial of Letrozole in postmenopausal women after five years of Tamoxifen therapy for early-stage breast cancer, N. Engl. J. Med., vol. 349, no. 19, p.1793–1802, (2003).

[20] E. M. Bailey, D. J. Krakovsky, M. J. Rybak, and D. Pharm, The triazole antifungal agents : A review of Itraconazole and Fluconazole, Pharmacotherapy, vol. 10, no. 2, p.146–153, (1990).

[21] R. P. Dickinson, A. S. Bell, C. A. Hitchcock, S. Narayanaswami, S. J. Ray, K. Richardson and P. F. Troke, Novel antifungal 2-aryl-1-(1H-1, 2, 4-triazol-1-yl)butan-2-ol derivatives with high activity against aspergillus fumigatus., Bioorg. Med. Chem. Lett., vol. 6, no. 16, p.2031–2036, (1996).

[22] A. N. A. Espinel-ingroff, S. Shadomy, and R. J. Gebhart, In Vitro Studies with R 51 , 211 ( Itraconazole ), Antimicrob. Agents Chemother., vol. 26, no. 1, p.5–9, (1984).

[23] J. B. Cohn, C. S. Wilcox, J. Bremner, and M. Ettinger, Hypnotic efficacy of Estazolam compared with Flurazepam in outpatients with insomnia, J. Clin. Pharmacol., vol. 31, no. 8, p.747–750, (1991).

[24] G. E. Pakes, R. N. Brogden, R. C. Heel, T. M. Speight, and G. S. Avery, Triazolam : A review of its pharmacological properties and therapeutic efficacy in patients with insomnia, Drugs, vol. 22, p.81–110, (1981).

[25] J. C. Verster and E. R. Volkerts, Clinical efficacy, and behavioral toxicity of Alprazolam: A review of the literature, CNS Drug Rev., vol. 10, no. 1, p.45–76, (2004).

[26] S. Subbarayan and M. Kipnes, Sitagliptin : A review, Expert Opin. Pharmacother, vol. 12, no. 10, p.1613–1622, (2011).

[27] D. Drucker, C. Easley, and P. Kirkpatrick, Sitagliptin, Nat. Rev. Drug Discov., vol. 6, no. February, p.109–110, (2007).

[28] D. A. Price, S. Gayton, M. D. Selby, J. Ahman, S. Haycock-lewandowski, B. L. Stammen, and A. Warren, Initial synthesis of UK-427 , 857 ( Maraviroc ), Tetrahedron Lett., vol. 46, p.5005–5007, (2005).

[29] Y. Zhu, S. H. Olson, D. Graham, G. Patel, A. Hermanowski-vosatka, S. Mundt, K. Shah, M. Springer, R. Thieringer, S. Wright, J. Xiao, H. Zokian, J. Dragovic, and J. M. Balkovec, Phenylcyclobutyl triazoles as selective inhibitors of 11β-hydroxysteroid dehydrogenase type I, Bioorg. Med. Chem. Lett., vol. 18, p.3412–3416, (2008).

[30] O. Bekircan and N. Gumrukcuoglu, Synthesis of some 3 , 5-diphenyl-4 H -1 , 2 , 4-triazole derivatives as antitumor agents, Indian J. Chem., vol. 44B, p.2107–2113, (2005).

[31] K. T. Potts, The chemistry of 1, 2, 4-triazoles, Chem. Rev., vol. 61, no. 2, p.87–127, (1961).

[32] A. Cetin and I. H. Gecibesler, Evaluation as antioxidant agents of 1, 2, 4-triazole derivatives: effects of essential functional groups, J. Appl. Pharm. Sci., vol. 5, no. 06, p.120–126, (2015).

[33] D. R. Godhani, A. A. Jogel, A. M. Sanghani, and J. P. Mehta, Synthesis and biological screening of 1 , 2 , 4-triazole derivatives, Indian J. Chem., vol. 54B, p.556–564, (2015).

Show More Hide